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doi:10.1016/j.jfma.2011.06.027Background/Purpose: Pneumococcal polysaccharide vaccination may be associated with
adverse outcomes in HIV-infected individuals who did not receive highly active antiretroviral
therapy (HAART). Our aim was to evaluate the impact of vaccination with seven-valent pneu-
mococcal conjugate vaccine (PCV) on the short-term clinical, virologic, and immunologic
outcomes among HIV-infected adult patients in the HAART era.
Methods: A total of 429 HIV-infected adult patients were enrolled from October 2008 to March
2010: 213 received two doses of seven-valent PCV given at a 4-week interval and 216 received
one dose. All patients were given 1-week diary to record any discomfort after vaccination.
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pneumoniaeResults: Of the 429 patients with a mean CD4 count of 305 cells/mL, 289 (67.4%) were receiving
HAART and 175 (40.8%) had plasma HIV RNA load <40 copies/mL at vaccination. Of the 396
patients (92.3%) who returned the diary, injection site soreness (24.0%) and pain (10.4%) were
the most commonly reported adverse effects. After 3e4 months of vaccination, CD4 count
increased by 40 cells/mL in 278 patients (68.2%) who continued HAART, compared with
a decrease of 38 cells/mL in 131 patients (31.8%) who were not on HAART (p < 0.001), while
the respective change in plasma HIV RNA load was 0.8 versus 0.2 log10 copies/mL
(p Z 0.09). One patient died, two developed opportunistic infections, and one developed
pneumococcal pneumonia following vaccination.
Conclusion: Vaccination with seven-valent PCV among HIV-infected patients is generally safe,
which has no detrimental effect on CD4 count and plasma HIV RNA load in patients receiving
HAART. (ClinicalTrials.gov number, NCT00885628).
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Patients with HIV infection have a higher incidence and
recurrence rate of invasive infections due to Streptococcus
pneumoniae compared with persons without HIV
infection.1e4 Before the introduction of highly active anti-
retroviral therapy (HAART), the rate of invasive pneumo-
coccal disease was 100-fold greater in HIV-infected patients
compared to HIV-uninfected controls.5 The incidence of
invasive pneumococcal disease in HIV-infected patients
remains as high as 35- to 60-fold compared to HIV-
uninfected adults in the HAART era.3,6
To reduce risk for invasive pneumococcal disease,
23-valent pneumococcal polysaccharide vaccine (PPV) is
recommended for HIV-infected adolescents and adults who
have a CD4 lymphocyte count S200 cells/ml.7 Clinical
observations among patients with access to HAART have
suggested that use of HAART and pneumococcal vaccination
are protective factors against invasive pneumococcal
disease.8e10 However, the randomized clinical trial of
23-valent PPV among HIV-infected patients who did not
receive HAART in Uganda showed an increased rate of
all-cause pneumonias in patients who received 23-valent
PPV compared with those who received placebo.11 While
the reasons for increased risk for adverse outcomes in HIV-
infected African patients receiving 23-valent PPV remains
unknown, the potential detrimental effects of vaccination
with PPV on HIV replication and CD4 depletion have become
a concern among HIV-infected patients who do not receive
HAART.
In 2000, the U.S. Food and Drug Administration approved
the seven-valent pneumococcal conjugate vaccine (PCV)
in children. PCV can induce a T-cell-dependent immune
response and memory T- and B-cells,12 which generates
better secondary antibody responses after reexposure to
the pathogen or revaccination. Clinical trials and pop-
ulation studies have demonstrated the beneficial effects of
seven-valent PCV in immunogenicity and decreasing inci-
dences of invasive pneumococcal disease due to vaccine
serotypes of S pneumoniae in vaccinated children.13e16
Several serologic studies have also demonstrated favor-
able immunogenicity and opsonophagocytic activity in
HIV-infected patients who receive seven-valent PCV.17e20
A recent randomized clinical trial in Malawi estimated
an efficacy of 74% in reduction of recurrent invasivepneumococcal disease due to vaccine serotypes among
HIV-infected African adults compared with those who
received placebo.21 Notwithstanding, studies reporting the
impact of seven-valent PCV vaccination on HIV replication
and CD4 counts in HIV-infected adult patients are sparse. In
this study, we aimed to assess the impact of seven-valent
PCV vaccination on serial short-term changes of CD4
counts and plasma HIV RNA load in HIV-infected patients
with access to HAART.
Materials and methods
Study population
HIV-infected adults aged 20 years or older who had no
previous history of pneumococcal vaccination were
recruited from infectious diseases clinics at the National
Taiwan University Hospital from October 2008 to March
2010. HIV infection was documented by enzyme-linked
immunosorbent assay and Western blot testing. Persons
with the following conditions were excluded: current
pregnancy, use of immunomodulating agents within the
past 3 months, or use of cytoreductive chemotherapy
within the last 6 months. The study was approved by the
Research Ethics Committee of the hospital, and the
participants gave written informed consent.
Vaccine administration
All eligible patients were consecutively enrolled in this
cohort study to receive one dose or two doses of seven-
valent PCV at a 4-week interval between the two doses that
was administered by study nurses via intramuscular deltoid
injections to examine if two-dose vaccination may provide
more durable serologic responses than one-dose vaccina-
tion.22 The seven-valent PCV (Prevenar, Wyeth-Lederle)
contains 2 mg of capsular polysaccharide from each of six
serotypes (4, 9 V, 14, 18C, 19F, and 23F) and 4 mg of capsular
polysaccharide from serotype 6B convalently linked to
a total of 20e25 mg of CRM197, a nontoxic mutant diphtheria
toxin. After receipt of a single 0.5-ml injection of PCV, all
patients were prospectively followed for 48 weeks.
Following receipt of PCV, all participants were given
a diary to record any adverse event for 7 consecutive days.
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severe adverse effects. Severe adverse reactions were
ascertained by interview with the participants by telephone
and hospitalization was arranged, if deemed necessary.
Laboratory investigations
Plasma HIV RNA load was quantified using the Cobas Ampli-
cor HIV-1 Monitor test (Cobas Amplicor version 1.5; Roche
Diagnostics Corporation, Indianapolis, IN, USA) with a lower
detection limit of 40 copies/mL, and CD4 count was deter-
mined using FACFlow (BD FACS Calibur; Becton Dickinson,
San Jose, CA, USA). CD4 count and plasma HIV RNA load were
monitored 1 month after initiation of HAART or change of
regimens in the face of virologic failure, and every 3 to 6
months thereafter according to the local HIV treatment
guidelines.
HAART was defined as the combination of at least three
antiretroviral agents containing two nucleoside reverse-
transcriptase inhibitors plus protease inhibitors or one
non-nucleoside reverse-transcriptase inhibitors, or triple
nucleoside reverse-transcriptase inhibitors.
Statistical analyses
All statistical analyses are performed using STATA statistical
software 8.0. Categorical variables were compared using c2Table 1 Characteristics of HIV-infected patients receiving seve
All pat
Patient number, n
Age at first vaccination, mean (SD), y
Male sex, n (%)
Risk factor for HIV transmission, n (%)
Homosexual
Heterosexual
IDU
Viral hepatitis
Chronic HBV infection
Anti-HCV antibody-positive
Comorbidities
Liver cirrhosis
Heart failure
Renal failure
Diabetes
Chronic obstructive pulmonary disease
Nadir CD4, mean (SD), cells/mL
CD4 < 200, n (%)
CD4 at first vaccination, mean (range), cells/mL
CD4 < 200, n (%)
CD4, 200e349
CD4 S 350
PVL at first vaccination, mean (SD), log10 copies/mL
PVL < 50 copies/mL, n (%)
PVL > 5 log10 copies/mL
On HAART, n (%)
HAART Z highly active antiretroviral therapy; HBV Z hepatitis B
PVL Z plasma HIV RNA load; SD Z standard deviation.or Fisher’s exact test, whereas noncategorical variables
were compared using Student’s t test. Differences in
plasma HIV RNA load and CD4 count within each individual
were compared by using paired two-sample for mean t test.
All tests are two-tailed and a p value <0.05 is considered
significant.
Results
Characteristics of study population
During the study period, 429 HIV-infected patients were
enrolled: 213 received two doses of seven-valent PCVand 216
received one dose. Table 1 summarizes the baseline clinical
characteristics of the participants. There were no significant
differences in terms of age, sex, risk factors, comorbidities,
nadir CD4 count, CD4 count at vaccination, plasma HIV RNA
load, and receipt of HAART and its duration between the two
groups. The mean duration of HAART for those who had
initiated HAART before vaccination was 334 days.
Clinical spectrum of adverse effects
In total, 396 patients (92.3%) were evaluated for adverse
events following PCV vaccination, and 33 patients (7.7%)
failed to return their diaries after vaccination, for whomn-valent pneumococcal conjugate vaccine.
ients Two-dose group One-dose group p
213 216
34.6 (0.7) 35.3 (0.7) 0.25
207 (97.2) 203 (94.0) 0.11
170 (79.8) 173 (80.1) 0.94
28 (13.2) 31 (14.4) 0.72
8 (3.8) 8 (3.7) 0.98
45 (22.6) 44 (22.6) 0.99
36 (17.7) 36 (18.1) 0.93
12 (6.0) 12 (6.2) 0.96
16 (7.5) 13 (5.1) 0.30
5 (2.4) 4 (1.9) 0.75
3 (1.4) 2 (1.0) 0.66
0 (0) 2 (2.4) 0.15
4 (1.9) 5 (2.4) 0.73
6 (2.8) 2 (1.0) 0.16
273.2 (16.1) 278.7 (15.0) 0.40
94 (44.8) 81 (37.9) 0.15
426.6 (14.5) 442.1 (14.9) 0.23
29 (13.7) 27 (12.7) 0.75
55 (26.1) 45 (21.1) 0.23
127 (60.2) 141 (66.2) 0.20
2.7 (0.1) 2.9 (0.1) 0.05
94 (44.1) 81 (38.0) 0.20
10 (4.7) 13 (6.1) 0.52
147 (69.0) 142 (65.7) 0.47
virus; HCV Z hepatitis C virus; IDU Z injecting drug users;
Figure 1 (A) Mean CD4 changes in four groups of patients:
two-dose seven-valent pneumococcal conjugate vaccine (PCV)
(gray bar) versus one-dose (bar with dots) and receipt of highly
active antiretroviral therapy (HAART) (bar with vertical lines)
versus no HAART (white bar). (B) Mean CD4 changes in patients
with HAART and without HAART compared to their own base-
line CD4 counts at first vaccination in each group. Patients who
received two doses of PCV are displayed in gray bar; and
patients who received one dose of PCV are displayed in white
bar.
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(34.3%) reported at least one adverse event, with the most
common adverse event being injection site soreness that
was noted in 95 patients (24.0%), and pain, in 41 patients
(10.4%). Fever was noted in only five patients (1.3%). Other
adverse events included injection site redness or swelling,
fatigue, headache, or cough that was noted in a total of 19
patients (4.8%) (data not shown). None of the patients who
received two doses of PCV reported worsening of adverse
events or new adverse events after receipt of the second
dose. There was no statistically significant difference in
occurrences of adverse events between patients with one
or two doses of seven-valent PCV vaccination or between
patients with or without HAART.
Among the studied patients, only one patient died during
the 1-year follow-up. He died 154 days after two-dose PCV
vaccination due to hepatocellular carcinoma related to
chronic hepatitis B infection. One patient who received two
doses of PCV developed pneumococcal pneumonia 142 days
after PCV vaccination. Serotyping of the causative strain
could not be performed because the diagnosis of pneumo-
coccal pneumonia was made by clinical symptoms, chest
radiography, and positive pneumococcal antigen test of
a urine specimen at presentation. As for opportunistic
infection, one patient receiving two doses of PCV had
immunologic and virologic failure and oral candidiasis188
days after PCV vaccination due to poor adherence to
HAART, and another patient who received one dose PCV
was hospitalized for meningoencephalitis and myelitis due
to Mycobacterium avium complex 127 days after PCV
vaccination, for which immune reconstitution inflammatory
syndrome was diagnosed.Impact of PCV vaccination on CD4 count changes
and HIV replication
There were 410 (95.6%) and 418 (97.4%) patients who had
measurements of CD4 count and plasma HIV RNA load
before and after vaccination, respectively. Compared to
baseline, 229 patients (56.2%) had a mean CD4 count
increase by 100 cells/mL [standard deviation (SD), 95] after
a follow-up duration of 102 days, while 177 patients (43.5%)
had a decrease by 95 cells/mL (SD, 102) after a follow-up
duration of 107 days. In four patients, CD4 counts remained
unchanged after vaccination.
Fig. 1A summarizes the CD4 changes in four groups of
patients: two-dose versus one-dose PCV and receipt of
HAART versus no HAART. For the 207 patients (50.5%) who
received two doses of PCV, mean CD4 increased by 16.9
cells/mL (standard deviation [SD], 9.3) after a mean follow-
up duration of 109 days, compared with 12.8 cells/mL (SD,
9.9) for the 203 patients (49.5%) who received one dose
after a follow-up duration of 97 days (p Z 0.76). For the
278 patients (67.8%) who were receiving HAART before or at
vaccination, including three patients who started HAART
after vaccination (median interval, 96 days), CD4 count
increased by 40.1 cells/mL (SD, 7.6) after a follow-up
duration of 108 days, compared with a decrease of CD4
count by 38.4 cells/mL (SD, 12.5) for the 132 patients
(32.2%) who were not receiving HAART after a follow-up
duration of 94 days (p < 0.001). Regardless of doses ofPCV received, patients on HAART had increases of CD4
counts while those not on HAART had decreases of CD4
counts (Fig. 1B).
As for the mean changes of plasma HIV RNA load in the
four groups of patients, in 211 patients (50.5%) who
received two doses of PCV, plasma HIV RNA load decreased
by 0.2 log10 copies/mL (SD, 0.1) after a follow-up duration
of 97 days, compared to 0.2 log10 copies/mL (SD, 0.1) for
the 205 patients (49.0%) who received one dose of PCV after
a follow-up duration of 109 days (p Z 0.63). For the 286
patients (68.4%) who were receiving HAART at and after
vaccination, plasma HIV RNA load decreased by 0.2 log10
copies/mL (SD, 0.1) after a follow-up duration of 107 days,
compared to 0.1 log10 copies/mL (SD, 0.1) for the 132
patients (31.6%) who were not receiving HAART after
a follow-up duration of 94 days (p Z 0.09).
Fig. 2 summarizes the changes of CD4 counts (Fig. 2A)
and plasma HIV RNA load (Fig. 2B) of the patients who had
measurements of CD4 counts within 30 and 60 days
following vaccination. In total, 32 patients had two
measurements of CD4 counts within 30 days after vaccina-
tion (mean interval, 21.3 days); among these, 27 (84.4%)
were receiving HAART and their CD4 count increased from
330 to 392 cells/mL (p Z 0.005); and five (15.6%) were
not taking HAART whose CD4 count decreased from 449 to
443 cells/mL (p Z 0.95). A total of 66 patients had two
measurements of CD4 counts within 60 days following
vaccination (mean interval, 36.6 days); among these, 53
(80.3%) were receiving HAART and their CD4 count
increased from 375 to 444 cells/mL (p Z 0.001), and 13
(19.7%) were not taking HAART whose CD4 count increased
from 421 to 454 cells/mL (p Z 0.33).
Figure 2 (A) CD4 changes of patients who had measurements
of CD4 count within 30 and 60 days following vaccination
compared to baseline CD4 count at vaccination in each group.
Patients who were on HAART are displayed in gray bar and
those patients who were not on HAART are displayed in white
bar. (B) Changes of plasma HIV RNA load of patients who had
measurements within 30 and 60 days following vaccination
compared to HV RNA load at vaccination in each group.
Patients who were on HAART are displayed in gray bar and
patients who were not on HAART are displayed in white bar.
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HIV RNA load within 30 days after vaccination (mean
interval, 20.5 days); among these, 29 patients (85.3%) were
receiving HAART and their plasma HIV RNA load decreased
from 3.0 (SD, 0.3) to 2.2 (SD, 0.2) log10 copies/mL
(p < 0.001); and in five (14.7%) who were not taking HAART,
plasma HIV RNA load decreased from 4.6 (SD, 0.4) to 4.5
(SD, 0.2) log10 copies/mL (pZ 0.58) (Fig. 2B). A total of 68
patients who had two measurements of plasma HIV RNA
load within 60 days after vaccination (mean interval, 41.0
days); among these, 55 (80.9%) were receiving HAART
and their plasma HIV RNA load decreased from 2.5 (SD, 0.2)
to 1.9 (SD, 0.1) log10 copies/mL (p < 0.001); and in 13
(19.1%) who were not taking HAART, plasma HIV RNA
load decreased from 4.5 (SD, 0.3) to 4.3 (SD, 0.2) log10
copies/mL (p Z 0.13).
Discussion
In this prospective cohort study, we found that self-limited
injection-related adverse events occurred in 34.3% HIV-
infected adult patients who received seven-valent PCV.
PCV vaccination had no detrimental effect on CD4 count
and HIV replication in patients who were receiving HAART
before and after receipt of seven-valent PCV.
Following the licensure of seven-valent PCV in the
United States and several developed countries for preven-
tion of invasive pneumococcal disease among children,many investigators started to assess the efficacy and safety
of seven-valent PCV among elderly or adults with immu-
nocompromising diseases, such as solid-organ trans-
plantation and HIV infection.17,18,23,24 These studies
demonstrated that 10.9e62.5% of adults developed local or
systemic reactions following vaccination.17,20,23e25 The
differences in frequency of reactogenicity among these
studies may be caused by the different study populations
and vaccination strategies. In HIV-infected patients
receiving PCV only, the incidence of adverse effects ranged
from 10.9% to 49.1%.17,18,20 Although fever was reported in
3.3e13% of the vaccinated HIV-infected children,26,27 only
1% of the vaccinated HIV-infected adults in our study re-
ported fever.
The frequency of reactogenicity may be related to the
vaccine used and doses administered and strategies of
booster vaccination. Feikin and colleagues17 had shown
that HIV-infected adult patients who received PCV tended
to have more local symptoms than those who received PPV,
although significant difference was noted only for arm
movement limitation. Similar to the findings of Feikin and
colleagues,17 we found that the patients who received two
doses of PCV at an interval of 1 month did not develop new
or worsening symptoms on receipt of the second dose of
PCV.
French and colleagues11 reported that HIV-infected
African patients without HAART who received 23-valent
PPV had increased rates of all-cause pneumonias within
the first 6 months of PPV vaccination. One of the explana-
tions for this finding may be the transient increase in
replication of HIV-1 within CD4 cells caused by the vacci-
nation.28 HIV-infected adult patients on HAART who
received PPV vaccination showed no deleterious effect on
CD4 and plasma HIV viral load 4 weeks after PPV vaccina-
tion.9,28 Similarly, Feikin and colleagues17 reported that
there was no significant increase in plasma HIV RNA load
8 weeks after the first and the second dose of PCV in
HIV-infected adult patients. However, only 15 patients
were evaluated in their study, and all study participants
had a mean baseline plasma HIV RNA load of less than 5000
copies/mL. In another study of 106 patients who were
enrolled for PCV and PPV vaccination administered at an
interval of 4 weeks, there were also no significant changes
in CD4 counts and plasma HIV RNA load during the 24-week
follow-up. However, detailed descriptions of the serial
changes of CD4 and plasma HIV RNA load after each
vaccination and the effect of HAART on these changes are
lacking.18 In this study, we found that there were no
significant changes of plasma HIV RNA load in patients who
were not taking HAART at and after PCV vaccination,
although there was a nonsignificant decrease of CD4 count.
In contrast, a significant decrease in plasma HIV RNA load
and increase of CD4 count were observed in patients who
were taking HAART, which may explain the rare occurrence
of HIV-related complications in those patients. These find-
ings may inform and reassure the investigators to conduct
randomized clinical trials using PCV to prevent invasive
pneumococcal diseases among HIV-infected patients who
are also eligible for initiation of HAART.
There were several limitations in our study, and inter-
pretation of our data should be applied with caution. First,
the symptoms of reactogenicity were subjective and not
450 C.-L. Lu et al.quantified. Second, this study results may not be general-
ized to the HIV-infected elderly patients who need vacci-
nation most, because only 26 (6.1%) study participants were
aged 55 years or older in our study (data not shown). Among
these 26 patients, 24 patients (92.3%) returned the adverse
events report and seven (29.1%) patients experienced local
adverse events following vaccination (data not shown).
None of the adverse events were severe. Third, there was
no placebo arm in our study. Therefore, we are not able to
evaluate to what extent PCV may impact on CD4 and
plasma HIV RNA load compared with placebo. Fourth,
patients with available CD4 counts and plasma HIV RNA
loads 30 and 60 days after PCV vaccination were small (32
and 66 patients, respectively, for CD4 counts and 34 and 68
patients, respectively, for plasma HIV RNA load). There-
fore, we were not able to precisely examine the immediate
effect on CD4 and plasma HIV RNA load of PCV vaccination.
Fifth, this study was conducted in a country with free-of-
charge access to HAART and therefore, these results may
not be generalized to the resource-limited countries where
access to HAART remains difficult.
In conclusion, seven-valent PCV vaccination is safe
among HIV-infected adult patients with access to HAART.
Vaccination with seven-valent PCV has no detrimental
effect on CD4 count and HIV replication in HIV-infected
adult patients who received HAART.
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